Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

VisionGate Inc.

This article was originally published in Start Up

Executive Summary

In early 2001, after leaviing his post as executive chairman of TriPath Imaging, Alan Nelson founded VisionGate Inc., which is focused on developing a test for lung cancer screening. The technology he designed directly measures and quantifies structural changes in chromatin indicative of early-stage lung cancer, and uses proprietary optical microscopy that enables 3-D analysis. The result, he believes, is the first effective clinical screening test for this almost always fatal disease.

You may also be interested in...



Overcoming Skepticism About Cancer Diagnostics

In cancer diagnostics skepticism and optimism exist side by side. This is evident from a growing dichotomy between the spurt of early research projects, fueled by new technologies and increased government spending, and the lack of investor interest. Despite a brutal financing market and past disappointments, a few start-ups determined to address the field's unmet needs are pursuing development of new markers and detection technologies and gaining momentum.

Smear Campaign

Pap smears, unlike most other high-volume tests, are manual, subjecting them to human error and inexact judgments. To offset these deficiencies, scientists have been working for nearly three decades to develop automated screening systems, endeavors that until recently were littered with failures.

The Twisted Tale of Automated Pap Smear Screening

After a long history of failures by companies developing new Pap smear testing technologies, a small group of companies seem close to commercializing systems that could transform cytology testin by automating at least a part of the procedure. But these companies have yet to prove to potential users that their instruments save money in the long term and greatly improve quality for a test that most lab users believe already has a relatively low error rate.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

MT037315

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel